Drug Profile

Epoetin alfa biosimilar - Daewoong Pharmaceutical

Alternative Names: Epodion; Recombinant EPO - Daewoong Pharmaceutical; Recombinant human erythropoietin - Daewoong Pharmaceutical

Latest Information Update: 20 Jan 2020

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Daewoong Pharmaceutical
Class Antianaemics; Polyethylene glycols; Recombinant erythropoietins; Recombinant fusion proteins
Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Anaemia

Most Recent Events

08 Jan 2020 Daewoong Infion announces intention to file regulatory applications for Anaemia in Middle East countries
01 Apr 2017 Launched for Anaemia in Indonesia (SC)
01 Dec 2016 Registered for Anaemia in Indonesia (SC)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com